Eisai is expanding the scope of its cancer drug pipeline through a partnership with Bliss Biopharmaceutical, whose lead program addresses a hot oncology target that makes it a potential competitor to a blockbuster AstraZeneca product.
Under the collaboration agreement announced Monday,…
Source: medcitynews.com – Read more
CISA extends comment period for proposed rule on cyber incident reporting | AHA News – American Hospital Association
The Cybersecurity and Infrastructure Security Agency (CISA) has extended the comment period for a proposed rule on cyber incident reporting, as announced by the American